| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reviews |
Department of Biochemistry and Molecular Biology, Pennsylvania State University College of Medicine, Penn State Hershey Cancer Institute, Hershey, Pennsylvania
Requests for reprints: Karam El-Bayoumy, Biochemistry and Molecular Biology Department, H171, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033. Phone: 717-531-1005; Fax: 717-531-0002; E-mail: kee2{at}psu.edu.
Key Words: selenium chemoprevention chemotherapy prostate cancer survivors
The lack of treatment for "worried well" patients with high-grade prostatic intraepithelial neoplasia combined with issues of recurrence and hormone resistance in prostate cancer survivors remains a major public health obstacle. The long latency of prostate cancer development provides an ample opportunity to intervene with mechanistically based chemopreventive agents at various stages of disease progression. Our rationale for selenium intervention is based on current mechanistic knowledge derived solely from preclinical investigations. Clearly, there is sufficient scientific support for its entry into current clinical trials, the outcome of which will be highly valuable in assessing whether selenium can be recommended for cancer survivors. [Cancer Res 2009;69(7):2699–703]
This article has been cited by other articles:
![]() |
J. Li, J. C. Tharappel, S. G. Han, A. H. Cantor, E. Y. Lee, C. G. Gairola, and H. P. Glauert Effect of Dietary Selenium and Cigarette Smoke on Pulmonary Cell Proliferation in Mice Toxicol. Sci., October 1, 2009; 111(2): 247 - 253. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |